Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;52(3):791-796.
doi: 10.1007/s11239-021-02445-z. Epub 2021 Apr 9.

Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension

Mateo Porres-Aguilar  1   2 , Marius M Hoeper  3 , Belinda N Rivera-Lebron  4 , Gustavo A Heresi  5 , Debabrata Mukherjee  6 , Victor F Tapson  7
Affiliations
Review

Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension

Mateo Porres-Aguilar et al. J Thromb Thrombolysis. 2021 Oct.

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) represents the later stage consequence of at least one or more unresolved episodes of acute pulmonary embolism; thus, indefinite anticoagulation is strongly recommended by current practice guidelines. Historically, vitamin K antagonists have been widely used in these patients. However, recent data indicate a shift toward direct oral anticoagulants (DOACs), despite lack of data on the safety and efficacy in this patient population. Herein, we briefly discuss the current rationale for oral anticoagulation use in CTEPH, addressing important issues and controversies involved with the use of DOACs, opening a strategy for further clinical research in the field of oral anticoagulation.

Keywords: Chronic thromboembolic pulmonary hypertension; Direct oral anticoagulants; Oral anticoagulation; Pulmonary embolism; Venous thromboembolism; Vitamin K antagonists; Warfarin.

PubMed Disclaimer

References

    1. Fernandes T, Auger W, Fedullo P (2018) Epidemiology and risk factors for chronic thromboembolic pulmonary hypertension. Thromb Res 164:145–149 - DOI
    1. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mariuhu AT et al (2017) Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. https://doi.org/10.1183/13993003.01792-2016 - DOI - PubMed
    1. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I et al (2020) ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 17:2002828. https://doi.org/10.1183/13993003.02828-2020 - DOI
    1. Kramm T, Wilkens H, Fuge J, Schaffers HJ, Guth S, Weidenroth CB, Weingard B et al (2018) Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Res Cardiol 107:548–553 - DOI
    1. Sakao S, Tatsumi K (2013) Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: perspective. Histol Histopathol 28:185–193 - PubMed

MeSH terms

LinkOut - more resources